Arrowhead Pharmaceuticals has closed
the license and collaboration agreement with Amgen regarding the RNAi ARC-LPA
program.
The agreement fell through because of the early termination
of the waiting period according to the Hart-Scott Rodino Antitrust Improvements
Act of 1976.
Arrowhead, Amgen license and collaboration agreement closed
Alerts Sign-up